{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:18:10Z","timestamp":1790000290817,"version":"4.0.1"},"reference-count":26,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2308085QH268"],"award-info":[{"award-number":["2308085QH268"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health development promotion project. Spark program","award":["XHJH-0063"],"award-info":[{"award-number":["XHJH-0063"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>ALK rearrangements define an important molecular subtype of lung adenocarcinoma, and the rearranged ALK serves as a well-established oncogenic driver in this malignancy. The most common type of mutation is the EML4-ALK fusion. Meanwhile, rare fusions are also frequently discovered with regard to ALK. However, clinical efficacy varies substantially across rare ALK fusion variants due to their distinct biological features, and individualized drug selection guided by fusion architecture and tumor characteristics is therefore required. This case presents the entire treatment process of a female patient with advanced lung adenocarcinoma who had an OSBPL9-ALK fusion. The patient was diagnosed in early 2021; by referring to previous reports and model prediction with AlphaFold 2 and Autodock Pymol, the new second-generation ALK inhibitor Ensartinib was chosen. After 24 months, due to disease progression, she switched to the third-generation ALK inhibitor, Lorlatinib, after model prediction. After 15 months, for further disease progression, the anti-angiogenic drug, anlotinib, was added to the treatment plan. Unfortunately, 6 months later, the disease progressed further, and the patient chose supportive treatment for economic reason. Nine months later, the patient died. The presentation of this case will provide a reference guideline for the subsequent treatment of lung adenocarcinoma with the same fusion. Meanwhile, model-based prediction for ALK fusion targeted therapy can provide a predictive reference for drug selection in patients presenting similar ALK rearrangements in the future.<\/jats:p>","DOI":"10.3390\/healthcare14183085","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:50:03Z","timestamp":1789995003000},"page":"3085","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of an Advanced NSCLC Patient with a Rare OSBPL9-ALK Fusion: A Case Report"],"prefix":"10.3390","volume":"14","author":[{"given":"Liang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Respiration, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu 241000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiration, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu 241000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu 241000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu 241000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhepeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu 241000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1758834010397569","article-title":"Genotype-driven therapies for non-small cell lung cancer: Focus on EGFR, KRAS and ALK gene abnormalities","volume":"3","author":"Gaughan","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/1061186X.2022.2085730","article-title":"ROS1-positive non-small cell lung cancer (NSCLC): Biology, diagnostics, therapeutics and resistance","volume":"30","author":"Yu","year":"2022","journal-title":"J. Drug Target."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.21037\/tlcr-22-566","article-title":"Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: A narrative review","volume":"12","author":"Chen","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_11","first-page":"112","article-title":"EML4-ALK fusion gene in lung cancer and its biological function","volume":"15","author":"Yang","year":"2012","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","article-title":"KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer","volume":"15","author":"Takeuchi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/cge.13891","article-title":"SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma","volume":"99","author":"Liang","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107797","DOI":"10.1016\/j.lungcan.2024.107797","article-title":"Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma","volume":"191","author":"Wang","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7816","DOI":"10.3390\/curroncol29100618","article-title":"Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer","volume":"29","author":"Xiang","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12967-021-02982-4","article-title":"Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers","volume":"19","author":"Xia","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.21037\/tlcr-23-656","article-title":"An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: A case report","volume":"12","author":"Li","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bouchard, N., and Daaboul, N. (2025). Lung Cancer: Targeted Therapy in 2025. Curr. Oncol., 32.","DOI":"10.20944\/preprints202502.0162.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_22","first-page":"925","article-title":"Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials","volume":"2","author":"Agrawal","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70040","DOI":"10.1111\/crj.70040","article-title":"Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44-ALK Fusion: A Case Report and Literature Review","volume":"18","author":"Chen","year":"2024","journal-title":"Clin. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cac2.12524","article-title":"Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study","volume":"44","author":"Zheng","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/CMAR.S283199","article-title":"Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC","volume":"14","author":"Yun","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Luo, Y., and Ouyang, W. (2025). Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1594072"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/18\/3085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:36:58Z","timestamp":1789997818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/18\/3085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":26,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["healthcare14183085"],"URL":"https:\/\/doi.org\/10.3390\/healthcare14183085","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}